

Ovulation Induction in Anovulatory Patients with Polycystic Ovary Syndrome

Stefano Palomba, Angela Falbo, Tiziana Russo, Annalisa Di Cello, Fulvio Zullo

Department of Obstetrics and Gynecology, University "Magna Graecia" of Catanzaro, Italy

Correspondence: Stefano Palomba, Department of Obstetrics and Gynecology, University "Magna Graecia" of Catanzaro, Via Tommaso Campanella 182/1-88100 Catanzaro, Italy, e-mail: stefanopalomba@tin.it

Abstract

Ovarian dysfunction is probably the pivotal feature of polycystic ovary syndrome (PCOS) making this syndrome a major cause of anovulatory infertility in developed countries. Several approaches have been proposed to induce ovulation in PCOS patients. Notwithstanding lifestyle modifications, clomiphene citrate, surgery and, finally, gonadotropins are the classical and still effective therapeutic options. New drugs, such as metformin and aromatase inhibitors are today available in the treatment of anovulation related to PCOS. The aim of the present review is to describe all therapeutic approaches to the anovulatory PCOS patients.

Keywords: Anovulation, Infertility, Ovulation induction, PCOS, Treatments.

INTRODUCTION

Polycystic ovary syndrome (PCOS) is a common female disorder of fertile age.

The pathogenesis still today remains not completely clear. However, the syndrome is characterized by an increased frequency of LH pulse over FSH favoring the androgen production by ovarian theca cells and the increase of 17β -estradiol conversion in granulosa cells. Insulin also plays a key role in the pathogenesis of PCOS acting synergically with LH on theca cells, and reducing the sex hormone binding globulin (SHBG) and, thus increasing the biologically active androgen levels. In addition, several paracrine and autocrine factors mediate the effect of LH and insulin.

Several criteria were proposed to define PCOS.^{1,2} The Rotterdam consensus workshop concluded that PCOS is a syndrome of ovarian dysfunction and its diagnosis is confirmed by the presence of two of the following three disorders: oligomenorrhea or amenorrhea, hyperandrogenism (e.g. hirsutism, acne, alopecia) or hyperandrogenemia (e.g. elevated levels of total or free testosterone), and polycystic ovaries on ultrasonography (Fig. 1).²

According to the ESHRE/ASRM criteria, different phenotypes of PCOS patients can be distinguished including both anovulatory and ovulatory women,³ furthermore anovulation remains a key problem of the syndrome. Because ~75% of anovulatory infertility cases are associated with PCOS, it represents a heavy social burden. Here we describe the procedures used to induce ovulation in PCOS patients, medical treatments and the surgical approach.

DIET, PHYSICAL ACTIVITY AND WEIGHT LOSS

Obesity and overweight are common features in the PCOS patients and they carry many health consequences, including

some reproductive disorders. Several evidences demonstrated a relationship between obesity and infertility.⁴ In fact, obesity is often related to insulin resistance and associated hyperinsulinemia plays a pivotal role in ovarian steroidogenesis and androgen blood transport and/or activity in the target tissues.⁵ Obese PCOS women are more likely to suffer from hirsutism and infertility than normal-weight PCOS subjects.^{6,7} A wide study on PCOS women has shown that the sterility rate is about 40% higher in women with a body mass index (BMI) >30 compared to those with a BMI < 30.⁷ Only 12 to 22% of these obese women had regular menstrual cycles vs 28 to 32% of normal-weight women.⁷

Weight loss improves ovary function in obese PCOS women, probably by affecting obesity-related hyperinsulinemia.^{8,9} A loss of at least 5% of the body mass often leads to restoration of a normal menstrual cycle in PCOS obese women with amenorrhea.^{8,10} Weight loss also improves the pregnancy rate in untreated PCOS patients¹¹ and in women who have undergone fertility treatment.^{12,13} Finally, in PCOS patients, a low protein diet seems to be superior to a high protein diet in terms of endocrine change.¹⁴

Therefore, weight loss should represent the first-line approach in the treatment of obese and overweight PCOS women, since it significantly improves hormonal and metabolic abnormalities and may favor spontaneous ovulation and improve fertility rate in the majority of patients. Weight loss associated with a moderate physical activity is desirable because physical exercise reduces insulin resistance.¹⁵

CLOMIPHENE CITRATE (CC)

Since 1962, CC has been used for ovulation induction in anovulatory infertility.¹⁶ Studies on CC treatment in PCOS




Fig. 1: A diagnostic workout according to the ESHRE/ASRM criteria²




Fig. 2: Different treatment choices to induce ovulation in PCOS patients

women have demonstrated an ovulation rate of 60 to 85%, a pregnancy rate of 30 to 40%, and a miscarriage rate of 13 to 25%.¹⁶ CC acts at central level with an agonist effect on estrogen receptor (ER) decreasing the negative feedback of estrogens and increasing the gonadotropins pulse frequency, which in turn induces ovulation¹⁷ whereas at peripheral level, it antagonizes ER affecting negatively the endometrial and/or cervical factor.¹⁸⁻²¹ Although endometrial thickness is not

necessarily predictive of pregnancy in CC-stimulated cycles,²² the simultaneous administration of estrogens after ovulatory follicle selection has been recommended.²³⁻²⁵ *In vitro*, CC interferes with the ovarian production of LH receptors and could, thus, reduce progesterone production.²⁶ There is some controversy about the quality of oocytes after CC administration^{27,28} and decrease in uterine blood flow at uterine level during the implantation phase.²⁹ CC is cheap and easy to

administer with rare side effects, and induces follicular growth very similar to spontaneous growth. A meta-analysis demonstrated that CC is really effective to induce ovulation in PCOS patients.³⁰ However, high CC doses have been associated with ovarian hyperstimulation and multiple pregnancies albeit infrequently.¹⁶ Standard practice is to administer CC for 5 days from the second or third day of the menstrual cycle, starting with 50 mg/day and increasing to 250 mg/day. When ovulation did not occur after 3-4 cycles of CC treatment at the maximum dosage, a patient is classically defined "CC-resistant". To date, a PCOS woman is defined "CC-resistant" when ovulation is not achieved after 3 cycles of CC at 150 mg/day. In fact "managed care" studies³¹ have shown that the most effective dosage is 100 to 150 mg/day and over 75% of ovulations occur already within a dosage of 100 mg/day.³¹

GONADOTROPINS

When a patient is "CC-resistant" or when pregnancy is not achieved after 6 ovulation cycles with CC, the traditional option is to administer gonadotropins,³² which, however, are associated with an enhanced risk of multiple pregnancies and ovarian hyperstimulation particularly higher in PCOS patients.^{33,34}

There is little evidence to support the administration of urinary FSH (uFSH) instead of human menopausal gonadotropin (HMG) to induce ovulation in PCOS patients (Fig. 2).³⁵ However, two preparations induce ovulation without any difference in pregnancy rate and uFSH is associated with fewer cases of moderate and severe ovarian hyperstimulation syndrome (OHSS), and spontaneous abortions.³⁵ Thus, given their similar cost, uFSH should be more widely used.

Bayram et al reviewed studies comparing the use of uFSH, recombinant FSH (rFSH) and different FSH regimens in terms of safety, ovulation rate, pregnancy, abortion, multiple pregnancy and OHSS in CC-resistant PCOS patients.³⁶ No differences emerged between the two FSH preparations in any of the evaluated outcomes. Similarly, there were no differences between the usual "step-down" and "low-dose step-up" regimens.³⁶ On the other hand, in a study of 50 PCOS CC-resistant women, a "low-dose" rFSH regimen was more efficient and safer than uFSH.³⁷

The "low-dose" and "very-low-dose" step-up protocols consist of IM or SC administrations of FSH at a dose of 75 UI/day or 37.5 UI/day for 10 to 14 days. If follicle diameter is at least 10 mm and serum estradiol is 60 pg/ml, the FSH dose is maintained until the follicle measures 18 to 20 mm, at which point ovulation is induced with 10000 UI of hCG. Otherwise, the dose is increased by 37.5 UI/day for at least one week.³⁸ Pretreatment with gonadotropin-releasing hormone (GnRH) analogs does not significantly increase the rate of clinical pregnancy or reduce spontaneous miscarriages. On the contrary, it could increase the risk of OHSS.³⁹

SURGICAL APPROACH

Ovarian wedge resection has been the first surgical approach to PCOS⁴⁰ and, with the advent of laparoscopy, the surgery for PCOS is today gaining ground.⁴¹ In particular, the laparoscopic ovarian drilling (LOD), first performed in 1984,⁴² consists of performing three to six punctures with an insulated needle as perpendicularly as possible to the ovarian surface using a unipolar current.

The short-term effectiveness of LOD has been widely demonstrated whereas there are fewer data about the long-term effectiveness not only in terms of ovulation and pregnancy rate⁴³ but also regarding the restoration of the endocrine profile. In fact, Amer et al⁴⁴ reported that the beneficial endocrine and morphological effects of LOD appear to be sustained for up to 9 years in most PCOS patients.

It is not known why and how these surgical procedures act. It is possible that surgery alters the ovarian structures involved in androgenic production thereby causing a temporary decrease in testosterone, androstenedione and LH levels.⁴⁵⁻⁴⁷ Despite these LOD-induced hormonal changes, insulin resistance did not improve in normoinsulinemic women with PCOS,^{45,46} although it improved in a few hyperinsulinemic PCOS women subjected to LOD.⁴⁷ Stegmann et al⁴⁸ concluded that insulin resistance and adhesions at surgery were negatively associated with pregnancy in infertile PCOS women treated with LOD.

We do not know whether LOD or gonadotropins are the most effective means of inducing ovulation in CC-resistant patients with PCOS or not.^{49,50} A meta-analysis did not reveal clear differences in cumulative ongoing pregnancy rates between LOD and 6 cycles of gonadotropin-induced ovulation as primary treatment for anovulatory PCOS patients, although multiple pregnancy rates were considerably lower in women who conceived after LOD.⁵⁰ Bayram et al in a randomized controlled trial (RCT) have recently compared the effectiveness of an electrocautery strategy vs ovulation induction using recombinant follicle stimulating hormone in CC-resistant patients with PCOS concluding that both strategies were similarly effective in terms of ongoing pregnancy rate but the former strategy was related to a lower risk of multiple pregnancy.⁵¹ The same authors have performed an economic comparison between these procedures showing that the electrocautery strategy is less expensive in term of ovulation induction than rFSH.⁵²

LOD seems to increase ovarian response to gonadotropin for simple ovulation and IVF,^{53,54} and to reduce the risk of OHSS.⁵⁵ Finally, a recent RCT has shown that LOD is less effective and more expensive than metformin in CC-resistant PCOS women.⁵⁶

METFORMIN

Metformin cloridrate is an oral biguanide used in type-2 diabetes mellitus and recently introduced for the treatment of PCOS. It

has been well documented that the glucose metabolism is altered in PCOS and that the prevalence of hyperinsulinemia due to insulin resistance is higher in this syndrome than in healthy controls. Based on these considerations, insulin-sensitizing drugs, i.e. metformin could result useful in the management of PCOS patients. Several data show that metformin, administered initially at a low dose and subsequently building up to 1500 to 2500 mg daily, improves clinical and biochemical features of PCOS, restores regular menses, and induces ovulatory cycles in anovulatory CC-resistant or nonresistant patients.⁵⁷ In addition, metformin increased the ovulation and pregnancy rates in combination with CC in unselected and CC-resistant PCOS patients.⁵⁷

Metformin treatment is also related to poor side effects consisting of nausea, gastrointestinal symptoms, and very rarely to ketoacidosis.⁵⁷ Till present, metformin therapy could be considered a cheap, safe, and easy alternative to CC.⁵⁸ Recent data on anovulatory nonobese PCOS women, in fact, showed that metformin and CC were similarly efficacious to induce ovulation whereas pregnancy and abortion rates resulted significantly higher and lower, respectively, in women treated with metformin, while a trend was observed for the live-birth rate.⁵⁹

In addition, it has been demonstrated that metformin is more cost-effective than LOD as second-step procedure to treat overweight CC-resistant PCOS women.⁵⁶ The predictors of success of metformin therapy have not been demonstrated. In some studies^{60,61} metformin seems to be less effective in lean PCOS patients probably because insulin resistance is less pronounced and less frequent in lean PCOS patients, and hence the effect is less evident.⁶² In recent reports^{63,64} metformin was effective in nonobese/lean PCOS patients as well as in obese or/and overweight PCOS patients. In a controlled double-blind study metformin was not more effective than weight loss alone in obese PCOS patients⁶⁵ whereas in another controlled double-blind study, metformin and hypocaloric diet had a synergistic effect.⁶⁶ Finally, in extremely obese PCOS patients with a body mass index (BMI) higher than 35 kg/m², metformin did not improve the reproductive or endocrine outcomes compared with weight loss alone.⁶⁷ However, the latter study was uncontrolled and included ovulating PCOS women.⁶⁷

The effect of metformin in CC-resistant PCOS women treated with FSH is controversial.⁶⁸⁻⁷⁰ In one study, pretreatment with metformin for one month resulted in a more orderly follicular growth and a reduction in multifollicular development decreasing the ovarian hyperstimulation rate⁶⁸ whereas in another study metformin plus rFSH was not better than rFSH alone.⁶⁹ Palomba et al⁷⁰ have recently evaluated the effect of metformin pretreatment and coadministration in controlled ovarian stimulation (COS) followed by timed intercourse (TI) or intrauterine insemination (IUI). In this last study,⁷⁰ metformin increased the mono-ovulatory cycles and reduced the days of stimulation for noncancelled cycles and the number of vials of

gonadotropins used. Stadtmauer et al,^{71,72} in two retrospective studies, demonstrated that metformin decreases the risk of OHSS in CC-resistant PCOS women treated with gonadotropin and improves reproductive outcomes in IVF programs, also after the “coasting” procedure. Metformin also decreased the spontaneous abortion rate during the first trimester of pregnancy, which is above 50% in PCOS patients,⁷³ and improved cervical scores.⁷⁴

AROMATASE INHIBITORS

Aromatase is a cytochrome P450 that catalyzes the limitative reaction leading to estrone and estradiol production by conversion of androstenedione and testosterone.^{75,76} Aromatase inhibitors act by decreasing estrogen serum levels, thus inducing a positive feedback at a pituitary level and gonadotropins release,⁷⁶ which induces follicular growth. Follicular development is compatible with severe estrogen deficiency, and low or absent intrafollicular estrogen levels are compatible with regular follicular growth and development of fertilizable oocytes.⁷⁷ It is likely that follicular growth and oocyte maturation during treatment with aromatase inhibitors are secondary to increased androgen intrafollicular levels, which amplify the effects of FSH,^{78,79} and to the induction of high IGF-I intrafollicular concentrations, which synergize with FSH.⁸⁰ In PCOS patients, aromatase inhibitors induce ovulation without antiestrogenic effects on the endometrium.⁸¹ They were related with higher pregnancy rates and lower multiple pregnancy rates than CC and similar pregnancy rates to gonadotropins.⁸¹⁻⁸⁴ When compared with other ovarian stimulation treatments, pregnancies after letrozole were associated with similar miscarriage and ectopic pregnancy rates.⁸² The dose used was 2.5^{82,83,85} or 5⁸² mg/day of letrozole, administered from day 3 to 7 of the menstrual cycle or a single dose of 20 mg of letrozole on day 3 of the cycle.⁸⁶ With both treatment regimens, estradiol suppression peaked between 5 and 7 days of the cycle, estrogen levels rapidly decreased after day 7 and periovulatory LH peaked on days 13-14 of the cycle. Fisher et al⁸⁷ compared the administration (for 5 days from day 5 to day 9 of the cycle) of 2.5 mg/day letrozole with 50 mg/day CC in PCOS patients who underwent intrauterine injection. There was no significant difference in the number of follicles between CC-stimulated cycle and letrozole-stimulated cycle.⁸⁷ On the other hand, Fatemi et al⁸⁸ reported more follicles and a higher ovulation rate in PCOS patients who received 2.5 mg/day letrozole compared to 100 mg/day CC. Endometrial thickness at mid cycle was similar in two treatment regimens in both studies.^{87,88}

Data on aromatase inhibitors in IVF programs are still little.⁸⁹⁻⁹³ It is known that letrozole increases serum androstenedione and stimulates FSH receptor gene expression.⁹⁰ Aromatase inhibitors have been shown to decrease the number of FSH vials required to induce ovulation and the risk of OHSS, without antiestrogenic effects, in normal responders⁹¹ and in low responders^{92,93} treated with FSH.

CONCLUSION

The first-line approach in the treatment of obese PCOS women remains weight loss and regular physical activity. CC has been considered for many years the first-line therapy to induce mono-ovulation in PCOS women. Furthermore, till present, both CC and metformin can be considered the treatments of choice for mono-ovulation induction. Furthermore, more data need to be acquired before metformin can be considered the gold standard therapy from an endocrine viewpoint.

Gonadotropins may be considered as second-line treatment for ovulation induction in anovulatory patients after CC and metformin treatments alone or in combination, or in women who, having ovulate, did not conceive after 6 ovulatory cycles. Gonadotropins administration gives a high success rate but is related to extensive monitoring, high costs, and several complications. Among other experimental medical therapies, only aromatase inhibitors seem to hold promise for the treatment of anovulation in PCOS patients. In CC-resistant women with suspected organic gynecological disease, such as endometriosis or leiomyoma, LOD could be considerate a valid option, otherwise, it should be avoided because there are not evidences about its superior efficacy in comparison with the other therapeutic available options.

REFERENCES

- Zawdaki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: Towards a rational approach. In: Dunaif A, Given JR, Haseltine F, Merriam GR (Eds). Polycystic ovary syndrome. Boston: Blackwell 1992;377-84.
- The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-47.
- Carmina E, Longo MC, Rini GB, Lobo RA. Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters. J Clin Endocrinol Metab 2005;90:2545-49.
- Norman RJ, Noakes M, Wu R, Davies MJ, Moran L, Wang JX. Improving reproductive performance in overweight/obese women with effective weight management. Hum Reprod Update 2004;10:267-80.
- Pasquali R, Gambineri A. Role of changes in dietary habits in polycystic ovary syndrome. Reprod Biomed Online 2004;8:431-39.
- Franks S. Polycystic ovary syndrome: A changing perspective. Clin Endocrinol (Oxf) 1989;31:87-120.
- Balen AH, Conway GS, Kaltsas G, Techatrasak K, Manning PJ, West C, Jacobs HS. Polycystic ovary syndrome: The spectrum of the disorder in 1741 patients. Hum Reprod 1995;10:2107-11.
- Kiddy DS, Hamilton-Fairley D, Bush A, Short F, Anyaoku V, Reed MJ, Franks S. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1992;36:105-11.
- Guzick DS, Wing R, Smith D, Berga SL, Winters SJ. Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women. Fertil Steril 1994;61:598-604.
- Huber-Buchholz MM, Carey DG, Norman RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: Role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 1999;84:1470-74.
- Clark AM, Ledger W, Galletly C, Tomlinson L, Blaney F, Wang X, Norman RJ. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum Reprod 1995;10:2705-12.
- Clark AM, Thornley B, Tomlinson L, Galletley C, Norman RJ. Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment. Hum Reprod 1998;13:1502-05.
- Fedorcsak P, Dale PO, Storeng R, Tanbo T, Abyholm T. The impact of obesity and insulin resistance on the outcome of IVF or ICSI in women with polycystic ovarian syndrome. Hum Reprod 2001;16:1086-91.
- Moran LJ, Noakes M, Clifton PM, Tomlinson L, Norman RJ. Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:812-19.
- Mayer-Davis EJ, D'Agostino R JR, Karter AJ, Haffner SM, Rewers MJ, Saad M, Bergman RN. Intensity and amount of physical activity in relation to insulin sensitivity: The insulin resistance atherosclerosis study. JAMA 1998;279:669-74.
- Kousta E, White DM, Franks S. Modern use of clomiphene citrate in induction of ovulation. Hum Reprod Update 1997;3:359-65.
- Adashi EY. Clomiphene citrate: Mechanism(s) and site(s) of action: A hypothesis revisited. Fertil Steril 1984;42:331-44.
- Randall JM, Templeton A. Cervical mucus score and *in vitro* sperm mucus interaction in spontaneous and clomiphene citrate cycles. Fertil Steril 1991;56:465-68.
- Gonen Y, Casper RF. Sonographic determination of a possible adverse effect of clomiphene citrate on endometrial growth. Hum Reprod 1990;5:670-74.
- Nelson LM, Hershlag A, Kurl RS, Hall JL, Stillman RJ. Clomiphene citrate directly impairs endometrial receptivity in the mouse. Fertil Steril 1990;53:727-31.
- Li TC, Warren MA, Murphy C, Sargeant S, Cooke ID. A prospective, randomised, cross-over study comparing the effects of clomiphene citrate and cyclofenil on endometrial morphology in the luteal phase of normal, fertile women. Br J Obstet Gynaecol 1992;99:1008-13.
- Kolibianakis EM, Zikopoulos K, Fatemi HM, Osmanagaoglu K, Evenpoel J, Van Steirteghem A, Devroey P. Endometrial thickness cannot predict ongoing pregnancy achievement in cycles stimulated with clomiphene citrate for intrauterine insemination. Reprod Biomed Online 2004;8:115-18.
- Yagel S, Ben-Chetrit A, Anteby E, Zacut D, Hochner-Celnikier D, Ron M. The effect of ethinyl estradiol on endometrial thickness and uterine volume during ovulation induction by clomiphene citrate. Fertil Steril 1992;57:33-36.
- Shimoya K, Tomiyama T, Hashimoto K, Moriyama A, Kawamoto A, Tokugawa Y, Ohashi K, Saji F, Murata Y. Endometrial development was improved by transdermal estradiol in patients treated with clomiphene citrate. Gynecol Obstet Invest 1999;47:251-54.
- Gerli S, Gholami H, Manna C, Di Frega AS, Vitiello C, Unfer V. Use of ethinyl estradiol to reverse the antiestrogenic effects of

- clomiphene citrate in patients undergoing intrauterine insemination: A comparative, randomized study. *Fertil Steril* 2000;73:85-89.
26. Kessel B, Hsueh AJ. Clomiphene citrate augments follicle stimulating hormone-induced luteinizing hormone receptor content in cultured rat granulosa cells. *Fertil Steril* 1987;47:334-40.
 27. London SN, Young D, Caldito G, Mailhes JB. Clomiphene citrate induced perturbations during meiotic maturation and cytogenetic abnormalities in mouse oocytes in vivo and in vitro. *Fertil Steril* 2000;73:620-26.
 28. Oktay K, Berkowitz P, Berkus M, Schenken RS, Brzyski RG. The reincarnation of an old question clomid effect on oocyte and embryo? *Fertil Steril* 2000;73:620-26.
 29. Hsu CC, Kuo HC, Wang ST, Huang KE. Interference with uterine blood flow by clomiphene citrate in women with unexplained infertility. *Obstet Gynecol* 1995;86:917-21.
 30. Hughes E, Collins J, Vandekerckhove P. Clomiphene citrate for unexplained subfertility in women. *Cochrane Database Syst Rev* 2000;3.
 31. Gleicher N. Cost-effective infertility care. *Hum Reprod Update* 2000;6:190-99.
 32. ACOG technical bulletin. Managing the anovulatory state: Medical induction of ovulation. Number 197 September 1994. Committee on Technical Bulletins of the American College of Obstetricians and Gynecologists. *Int J Gynaecol Obstet* 1994;47:305-12.
 33. Garcea N, Campo S, Panetta V, Venneri M, Siccardi P, Dargenio R, De Tomasi F. Induction of ovulation with purified urinary follicle-stimulating hormone in patients with polycystic ovarian syndrome. *Am J Obstet Gynecol* 1985;151:635-40.
 34. Neyro JL, Barrenetxea G, Montoya F, Rodriguez-Escudero. Pure FSH for ovulation induction in patients with polycystic ovary syndrome and resistant to clomiphene citrate therapy. *Hum Reprod* 1991;6:218-21.
 35. Hughes E, Collins J, Vandekerckhove P. Ovulation induction with urinary follicle stimulating hormone vs human menopausal gonadotropin for clomiphene-resistant polycystic ovary syndrome. *Cochrane Database Syst Rev* 2000;4.
 36. Bayram N, van Wely M, van Der Veen F. Recombinant FSH vs urinary gonadotrophins or recombinant FSH for ovulation induction in subfertility associated with polycystic ovary syndrome. *Cochrane Database Syst Rev* 2001;2.
 37. Fulghesu AM, Apa R, Belosi C, Ciampelli M, Selvaggi L (Jr), Cucinelli F, Caruso A, Mancuso S, Lanzone A. Recombinant vs urinary follicle-stimulating hormone in the low-dose regimen in anovulatory patients with polycystic ovary syndrome: A safer and more effective treatment. *Horm Res* 2001;55:224-28.
 38. Strowitzki T, Seehaus D, Korell M, Hepp H. Low-dose FSH stimulation in polycystic ovary syndrome: Comparison of 3 FSH preparations. *Exp Clin Endocrinol Diabetes* 1998;106:435-39.
 39. Hughes E, Collins J, Vandekerckhove P. Gonadotrophin-releasing hormone analogue as an adjunct to gonadotropin therapy for clomiphene-resistant polycystic ovarian syndrome. *Cochrane Database Syst Rev* 2000;2.
 40. Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. *Am J Obstet Gynecol* 1935;29:181-91.
 41. Zullo F, Pellicano M, Zupi E, Guida M, Mastrantonio P, Nappi C. Minilaparoscopic ovarian drilling under local anesthesia in patients with polycystic ovary syndrome. *Fertil Steril* 2000;74:376-79.
 42. Gjonjaess H. Polycystic ovarian syndrome treated by ovarian electrocautery through the laparoscope. *Fertil Steril* 1984;41:20-25.
 43. Kriplani A, Manchanda R, Agarwal N, Nayar B. Laparoscopic ovarian drilling in clomiphene citrate-resistant women with polycystic ovary syndrome. *J Am Assoc Gynecol Laparosc* 2001;8:511-18.
 44. Amer SA, Banu Z, Li TC, Cooke ID. Long-term follow-up of patients with polycystic ovary syndrome after laparoscopic ovarian drilling: Endocrine and ultrasonographic outcomes. *Hum Reprod* 2002;17:2851-57.
 45. Lemieux S, Lewis GF, Ben-Chetrit A, Steiner G, Greenblatt EM. Correction of hyperandrogenemia by laparoscopic ovarian cautery in women with polycystic ovarian syndrome is not accompanied by improved insulin sensitivity or lipid-lipoprotein levels. *J Clin Endocrinol Metab* 1999;84:4278-82.
 46. Tulandi T, Saleh A, Morris D, Jacobs HS, Payne NN, Tan SL. Effects of laparoscopic ovarian drilling on serum vascular endothelial growth factor and on insulin responses to the oral glucose tolerance test in women with polycystic ovary syndrome. *Fertil Steril* 2000;74:585-88.
 47. Saleh A, Morris D, Tan SL, Tulandi T. Effects of laparoscopic ovarian drilling on adrenal steroids in polycystic ovary syndrome patients with and without hyperinsulinemia. *Fertil Steril* 2001;75:501-04.
 48. Stegmann BJ, Craig HR, Bay RC, Coonrod DV, Brady MJ, Garbaciak JA JR. Characteristics predictive of response to ovarian diathermy in women with polycystic ovarian syndrome. *Am J Obstet Gynecol* 2003;188:1171-73.
 49. Abdel Gadir A, Mowafi RS, Alnaser HM, Alrashid AH, Alonezi OM, Shaw RW. Ovarian electrocautery vs human menopausal gonadotrophins and pure follicle stimulating hormone therapy in the treatment of patients with polycystic ovarian disease. *Clin Endocrinol (Oxf)* 1990;33:585-92.
 50. Farquhar C, Vandekerckhove P, Lilford R. Laparoscopic "Drilling" by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. *Cochrane Database Syst Rev* 2001;4.
 51. Bayram N, van Wely M, Kaaijk EM, Bossuyt PM, van der Veen F. Using an electrocautery strategy or recombinant follicle stimulating hormone to induce ovulation in polycystic ovary syndrome: Randomised controlled trial. *BMJ* 2004;328:192.
 52. van Wely M, Bayram N, van der Veen F, Bossuyt PM. An economic comparison of a laparoscopic electrocautery strategy and ovulation induction with recombinant FSH in women with clomiphene citrate-resistant polycystic ovary syndrome. *Hum Reprod* 2004;19:1741-45.
 53. Rington MR, Walker SM, Shaw RW. The use of laparoscopic ovarian electrocautery in preventing cancellation of in vitro fertilization treatment cycles due to risk of ovarian hyperstimulation syndrome in women with polycystic ovaries. *Hum Reprod* 1997;12:1443-47.

54. Colacurci N, Zullo F, De Franciscis P, Mollo A, De Placido G. In vitro fertilization following laparoscopic ovarian diathermy in women with polycystic ovarian syndrome. *Acta Obstet Gynecol Scand* 1997;76:555-58.
55. Amin AF, Abd el-Aal DE, Darwish AM, Meki AR. Evaluation of the impact of laparoscopic ovarian drilling on Doppler indices of ovarian stromal blood flow, serum vascular endothelial growth factor, and insulin-like growth factor-1 in women with polycystic ovary syndrome. *Fertil Steril* 2003;79:938-41.
56. Palomba S, Orio F (Jr), Nardo LG, Falbo A, Russo T, Corea D, Doldo P, Lombardi G, Tolino A, Colao A, Zullo F. Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate-resistant women with polycystic ovary syndrome: A prospective parallel randomized double-blind placebocontrolled trial. *J Clin Endocrinol Metab* 2004;89:4801-09.
57. Costello MF, Eden JA. A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. *Fertil Steril* 2003;79:1-13.
58. Norman RJ. Editorial: Metformin—comparison with other therapies in ovulation induction in polycystic ovary syndrome. *J Clin Endocrinol Metab* 2004;89:4797-800.
59. Palomba S, Orio F (Jr), Falbo A, Manguso F, Russo T, Cascella T, Tolino A, Carmina E, Colao A, Zullo F. Prospective parallel randomized double-blind double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 2005;90:4068-74.
60. Nestler JE, Jakubowicz DJ. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. *J Clin Endocrinol Metab* 1997;82:4075-79.
61. Ng EH, Wat NM, Ho PC. Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene resistant polycystic ovaries: A randomized, double blinded placebo controlled trial. *Hum Reprod* 2001;16:1625-31.
62. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. *Diabetes* 1989;38:1165-74.
63. Maciel GA, Soares Junior (Jr), Alves Da Motta EL, Abi Haidar M, De Lima AR, Baracat EC. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. *Fertil Steril* 2004;81:355-60.
64. Kumari AS, Haq A, Jayasundaram R, Abdel-Wareth LO, Al Haija SA, Alvarez M. Metformin monotherapy in lean women with polycystic ovary syndrome. *R & Pro D. Biomed Online* 2005;10:100-04.
65. Crave JC, Fimbel S, Lejeune H, Cugnardey N, Dechaud H, Pugeat M. Effects of diet and metformin administration on sex hormone binding globulin, androgens, and insulin in hirsute and obese women. *J Clin Endocrinol Metab* 1995;80:2057-62.
66. Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D, Fiorini S, Cognigni GE, Filicori M, Morselli-Labate AM. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. *J Clin Endocrinol Metab* 2000;85:2767-74.
67. Ehrmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield RL, Polonsky KS. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 1997;82:524-30.
68. De Leo V, la Marca A, Ditto A, Morgante G, Cianci A. Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome. *Fertil Steril* 1999;72:282-85.
69. Yarali H, Yildiz B, Demiroglu A, Zeyneloglu HB, Yigit N, Bukulmez O, Koray Z. Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: A prospective randomized trial. *Hum Reprod* 2002;17:289-94.
70. Palomba S, Falbo A, Orio F (Jr), Manguso F, Russo T, Tolino A, Colao A, Dale B, Zullo F. A randomized controlled trial evaluating metformin pretreatment and coadministration in non-obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian hyperstimulation plus timed intercourse or intrauterine insemination. *Hum Reprod* 2005 Jun 15 (Epub ahead of print).
71. Stadtmayer LA, Toma SK, Riehl RM, Talbert LM. Metformin treatment of patients with polycystic ovary syndrome undergoing *in vitro* fertilization improves outcomes and is associated with modulation of the insulin-like growth factors. *Fertil Steril* 2001;75:505-09.
72. Stadtmayer LA, Toma SK, Riehl RM, Talbert LM. Impact of metformin therapy on ovarian stimulation and outcome in 'coasted' patients with polycystic ovary syndrome undergoing *in vitro* fertilization. *Reprod Biomed Online* 2002;5:112-16.
73. Glueck CJ, Phillips H, Cameron D, Sieve-Smith L, Wang P. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: A pilot study. *Fertil Steril* 2001;75:46-52.
74. Kocak M, Caliskan E, Simsir C, Haberal A. Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome. *Fertil Steril* 2002;77:101-06.
75. Cole PA, Robinson CH. Mechanism and inhibition of cytochrome P-450 aromatase. *J Med Chem* 1990;33:2933-42.
76. Akhtar M, Njar VC, Wright JN. Mechanistic studies on aromatase and related C-C bond cleaving P-450 enzymes. *J Steroid Biochem Mol Biol* 1993;44:375-87.
77. Palter SF, Tavares AB, Hourvitz A, Veldhuis JD, Adashi EY. Are estrogens of import to primate/human ovarian folliculogenesis? *Endocr Rev* 2001;22:389-424.
78. Weil S, Vendola K, Zhou J, Bondy CA. Androgen and follicle stimulating hormone interactions in primate ovarian follicle development. *J Clin Endocrinol Metab* 1999;84:2951-56.
79. Vendola KA, Zhou J, Adesanya OO, Weil SJ, Bondy CA. Androgens stimulate early stages of follicular growth in the primate ovary. *J Clin Invest* 1998;101:2622-29.
80. Giudice LC. Insulin-like growth factors and ovarian follicular development. *Endocr Rev* 1992;13:641-69.
81. Mitwally MF, Casper RF. Aromatase inhibitors for the treatment of infertility. *Expert Opin Investig Drugs* 2003;12:353-71.
82. Mitwally MF, Biljan MM, Casper RF. Pregnancy outcome after the use of an aromatase inhibitor for ovarian stimulation. *Am J Obstet Gynecol* 2005;192:381-86.

83. Mitwally MFM, Casper RF. The use of aromatase inhibitor for induction of ovulation in cases of clomiphene citrate failure. *Curr Opin Obstet Gynecol* 2002;14:255-63.
84. Mitwally MF, Casper RF. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. *Fertil Steril* 2001;75:305-09.
85. Sammour A, Bijan MM, Tan SL, Tulandi T. Prospective randomised trial comparing the effects of letrozole (LE) and clomiphene citrate (CC) on follicular development, endometrial thickness and pregnancy rate in patients undergoing superovulation prior to intrauterine insemination (IUI). *Fertil Steril* 2001;76(Suppl 1):S110.
86. Mitwally MF, Casper RF. Single-dose administration of an aromatase inhibitor for ovarian stimulation. *Fertil Steril* 2005;83:229-31.
87. Fisher SA, Reid RL, Van Vugt DA, Casper RF. A randomized double-blind comparison of the effects of clomiphene citrate and the aromatase inhibitor letrozole on ovulatory function in normal women. *Fertil Steril* 2002;78:280-85.
88. Fatemi HM, Kalibianakis E, Tournaye H, Camus M, Van Steirteghem AC, Devroey P. Clomiphene citrate vs letrozole for ovarian stimulation: A pilot study. *Reprod Biomed Online* 2003;7:543-46.
89. Hu Y, Cortvrindt R, Smits J. Effects of aromatase inhibition on *in vitro* follicle and oocyte development analyzed by early preantral mouse follicle culture. *Mol Reprod Dev* 2002;61:549-59.
90. Shetty G, Krishnamurthy H, Krishnamurthy HN, Bhatnagar S, Moudgal NR. Effect of estrogen deprivation on the reproductive physiology of male and female primates. *J Steroid Biochem Mol Biol* 1997;61:157-66.
91. Mitwally MF, Casper RF. Aromatase inhibition reduces gonadotrophin dose required for controlled ovarian stimulation in women with unexplained infertility. *Hum Reprod* 2003;18:1588-97.
92. Mitwally MF, Casper RF. Aromatase inhibition improves ovarian response to follicle-stimulating hormone in poor responders. *Fertil Steril* 2002;77:776-80.
93. Goswami SK, Das T, Chattopadhyay R, Sawhney V, Kumar J, Chaudhury K, Chakravarty BN, Kabir SN. A randomized single blind controlled trial of letrozole as a low-cost IVF protocol in women with poor ovarian response: A preliminary report. *Hum Reprod* 2004;19:2031-35.